Worldwide Pain Management Drugs Industry to 2030 – Rise in Number of Cases of Chronic Disorders is Driving Growth – PR Newswire

Searching for your content…
In-Language News
Contact Us
888-776-0942
from 8 AM – 10 PM ET
News provided by
Mar 04, 2022, 06:45 ET
Share this article
DUBLIN, March 4, 2022 /PRNewswire/ — The "Global Pain Management Drugs Market, By Drug Class, By Indication, By Pain Type, By Drug Type, By Distribution Channel, Estimation & Forecast, 2017 – 2030" report has been added to ResearchAndMarkets.com’s offering.
The global Pain Management Drugs market was valued at USD 71,238.7 Million in 2021 and is forecasted to reach USD 99,943.3 Million by the year 2030. The market is anticipated to register a CAGR of 3.92% over the projected period.

The pain management drugs market is anticipated to grow owing to the rise in number of cases of chronic disorders coupled with the rising healthcare expenditure and government support worldwide. Furthermore, growing number of surgical procedures and the increasing geriatric population are also estimated to fuel the market growth. However, the availability of alternatives such as pain reliever devices are expected to negatively impact the market growth.

Increasing incidence rate of chronic disorders is expected to boost the demand for pain management drugs for the treatment of pain associated with these disorders. According to the Centers for Disease Control and Prevention, as of December 2021, in the United States, 6 out of 10 adults suffer from a chronic disease and 4 out of 10 adults suffer from 2 diseases or more. These diseases include cancer, heart diseases, stroke, chronic lung disease, diabetes, Alzheimer’s disease, and chronic kidney disease. Most or all of these diseases are associated with pain. Hence the rise in the number of cases of chronic disorders are expected to fuel the market growth.

Segments Overview:
The global Pain Management Drugs market is segmented the drug class, indication, pain type, drug type, and distribution channel.

By Drug Class,
The opioids segment is estimated to hold the largest market share of around 31.9% owing to their increasing demand for relieving pain associated with major chronic disorders. The anesthetics segments is expected to surpass a market value of USD 9,000 million by 2026 and USD 11,764 million by 2030, owing to its high usage in surgeries.

By Indication,
The neuropathic pain segment is anticipated to account for the largest market share of more than 15% owing to rising cases of neuropathic pain. According to an article published by the National Center for Biotechnology Information in March 2019, the prevalence of neuropathic pain in general population ranges between 3% to 17%. Moreover, the market size for acute appendicitis segment is estimated to hot USD 3,598.0 million by 2030 owing to the increasing prevalence of acute appendicitis.

By Pain Type,
The acute pain segment is expected to hold the largest market share owing to the high popularity of acute pain management drugs globally and easy availability of these drugs through OTC distribution channels.

By Drug Type,
The branded segment is anticipated to grow at the fastest rate of around 4.1% over the projected period owing to the increasing popularity of branded drugs in the developed as well as developing economics.

By Distribution Channel,
The online segment’s market size is estimated to account for 34% of the hospital segment’s market size in 2021 and this share is expected to reach 37% by 2030. This is owing to the increasing number of e-pharmacy websites.

Regional Overview
Based on region, the global Pain Management Drugs market is divided into Europe, North America, Asia Pacific, South America, and Middle East & Africa.

The North America region is expected to hold the largest market share of more than 50% owing to the growing patient pool, rising geriatric population, and favourable regulatory scenario. According to the U.S. Census Bureau, as of August 2021, around 15.2 million people in the U.S., i.e. 1 in 6 or 16.5% of the population are aged 55 years and above.

Asia Pacific region witnessed the fastest growth rate of 5.33% during the forecast period owing to the rising healthcare expenditure and growing R&D investments. Furthermore, the presence of various generic players of pain management drugs in the region is also likely to contribute to the market growth.

Competitive Landscape
Key players operating in the global Pain Management Drugs market include Abbott Laboratories, Allergen Inc., Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly & Company, Endo Health Solutions, Inc., GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Ono pharmaceutical Co., Ltd., Pfizer, Inc., Purdue Pharma L.P., Sorrento Therapeutics, Valeant Pharmaceuticals International Inc., Viatris Inc., WEX Pharmaceuticals, Zynerba Pharmaceuticals, and Other Prominent Players.
Key Questions Answered:
Key Topics Covered:

Chapter 1. Research Framework
Chapter 2. Research Methodology

Chapter 3. Executive Summary: Global Pain Management Drugs Market

Chapter 4. Global Pain Management Drugs Market Overview
4.1. Industry Value Chain Analysis
4.1.1. Drugs Provider
4.1.2. Research and Development
4.1.3. Distributor
4.1.4. End Users
4.2. Industry Outlook
4.2.1. Pain relief techniques
4.3. PEST Analysis
4.4. Porter’s Five Forces Analysis
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Power of Buyers
4.4.3. Threat of Substitutes
4.4.4. Threat of New Entrants
4.4.5. Degree of Competition
4.5. Market Dynamics and Trends
4.5.1. Growth Drivers
4.5.2. Restraints
4.5.3. Challenges
4.5.4. Key Trends
4.6. Covid-19 Impact Assessment on Market Growth Trend
4.7. Market Growth and Outlook
4.7.1. Market Revenue Estimates and Forecast (US$ Mn), 2017-2030
4.7.2. Pricing Analysis
4.8. Competition Dashboard
4.8.1. Market Concentration Rate
4.8.2. Company Market Share Analysis (Value %), 2020
4.8.3. Competitor Product Mapping

Chapter 5. Global Pain Management Drugs Market Analysis, By Drug Class
5.1. Key Insights
5.2. Market Size and Forecast, 2017 – 2030 (US$ Mn)
5.2.1. NSAIDs
5.2.2. Anesthetics
5.2.3. Anticonvulsants
5.2.4. Anti-migraine Agents
5.2.5. Antidepressants
5.2.6. Opioids
5.2.7. Nonnarcotic Analgesics

Chapter 6. Global Pain Management Drugs Market Analysis, By Indication
6.1. Key Insights
6.2. Market Size and Forecast, 2017 – 2030 (US$ Mn)
6.2.1. Arthritic Pain
6.2.2. Neuropathic Pain
6.2.3. Cancer Pain
6.2.4. Chronic Back Pain
6.2.5. Postoperative Pain
6.2.6. Migraine
6.2.7. Fibromyalgia
6.2.8. Bone fracture
6.2.9. Muscle sprain
6.2.10. Acute appendicitis
6.2.11. Others

Chapter 7. Global Pain Management Drugs Market Analysis, By Pain Type
7.1. Key Insights
7.2. Market Size and Forecast, 2017 – 2030 (US$ Mn)
7.2.1. Chronic pain
7.2.2. Acute pain

Chapter 8. Global Pain Management Drugs Market Analysis, By Drug Type
8.1. Key Insights
8.2. Market Size and Forecast, 2017 – 2030 (US$ Mn)
8.2.1. Generics
8.2.2. Branded

Chapter 9. Global Pain Management Drugs Market Analysis, By Distribution Channel
9.1. Key Insights
9.2. Market Size and Forecast, 2017 – 2030 (US$ Mn)
9.2.1. Hospitals
9.2.2. Pharmacy Retail Stores
9.2.3. Online

Chapter 10. Global Pain Management Drugs Market Analysis, By Region/ Country
Chapter 11. North America Pain Management Drugs Market Analysis
Chapter 12. Europe Pain Management Drugs Market Analysis
Chapter 13. Asia Pacific Pain Management Drugs Market Analysis
Chapter 14. Middle East & Africa Pain Management Drugs Market Analysis
Chapter 15. South America Pain Management Drugs Market Analysis
Chapter 16. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
16.1. Abbott Laboratories
16.2. Allergen Inc.
16.3. Bayer AG
16.4. Boehringer Ingelheim
16.5. Bristol-Myers Squibb
16.6. Eli Lilly & Company
16.7. Endo Health Solutions, Inc.,
16.8. GlaxoSmithKline Plc.
16.9. Johnson & Johnson
16.10. Merck & Co. Inc.
16.11. Novartis AG
16.12. Ono pharmaceutical Co., Ltd.
16.13. Pfizer, Inc.
16.14. Purdue Pharma L.P.
16.15. Sorrento Therapeutics
16.16. Valeant Pharmaceuticals International Inc.
16.17. Viatris Inc.
16.18. WEX Pharmaceuticals
16.19. Zynerba Pharmaceuticals.
16.20. Other Prominent Players
For more information about this report visit https://www.researchandmarkets.com/r/u2trrn
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
More news releases in similar topics
Cision Distribution 888-776-0942
from 8 AM – 9 PM ET

source